Search hospitals > New Hampshire > Concord
New Hampshire Oncology Hematology PA-Concord
Claim this profileConcord, New Hampshire 03301
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
107 reported clinical trials
1 medical researcher
Summary
New Hampshire Oncology Hematology PA-Concord is a medical facility located in Concord, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. New Hampshire Oncology Hematology PA-Concord is involved with conducting 107 clinical trials across 144 conditions. There are 1 research doctors associated with this hospital, such as Douglas Weckstein, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Clinical Trials running at New Hampshire Oncology Hematology PA-Concord
Breast Cancer
Prostate Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Anal Squamous Cell Carcinoma
Rectal Cancer
Bladder Cancer
Prostate Adenocarcinoma
Squamous Cell Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Omitting Radiation Therapy
for Breast Cancer
This study is evaluating whether a type of radiation therapy may help prevent breast cancer from coming back.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at New Hampshire Oncology Hematology PA-Concord?
New Hampshire Oncology Hematology PA-Concord is a medical facility located in Concord, New Hampshire. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. New Hampshire Oncology Hematology PA-Concord is involved with conducting 107 clinical trials across 144 conditions. There are 1 research doctors associated with this hospital, such as Douglas Weckstein, MD.